Management ChangeJun 30, 2026, 08:46 AM
Dogwood Therapeutics Appoints Iain Dukes as Chair of New SAB
AI Summary
Dogwood Therapeutics, Inc. announced the appointment of Iain Dukes, Ph.D., as Chair of its newly formed Scientific Advisory Board (SAB). Dr. Dukes, a veteran biopharma industry executive and OrbiMed partner, will advise the company on scientific developments for its pipeline. Dogwood is advancing Halneuron® in Phase 2b for chemotherapy-induced neuropathic pain, with data expected in Fall 2026, and SP16 into Phase 1b for chemotherapy-induced peripheral neuropathy.
Key Highlights
- Iain Dukes, Ph.D., appointed Chair of Dogwood Therapeutics' new Scientific Advisory Board (SAB).
- Dr. Dukes is a veteran biopharma executive and OrbiMed partner.
- He previously served as SVP at Merck Research Laboratories and VP at Amgen.
- Dogwood's lead product, Halneuron®, is in Phase 2b for chemotherapy-induced neuropathic pain (CINP).
- Halneuron® Phase 2b data is anticipated in Fall 2026.
- SP16 received FDA clearance for Phase 1b development in chemotherapy-induced peripheral neuropathy (CIPN).
Price Impact
More from DWTX
Quarterly Result45m ago
Dogwood Therapeutics Reports Q3 Net Loss of $4.88M, Down from $15.74M
Quarterly ResultAug 13, 8:56 AM
Dogwood Therapeutics Q2 Net Loss $11.5M; Halneuron® Phase 2b on track
Quarterly ResultAug 13, 8:32 AM
Dogwood Therapeutics Halneuron® Phase 2b On Track; Antiviral Deal Up To $100M